Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tiagabine Hydrochloride

FDA-approved product (tablet, oral), marketed as Gabitril, Tiagabine Hydrochloride.

Registered studies
21
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tiagabine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fatty acid derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tiagabine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tiagabine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

    NCT00068770 · start 2003-10

    Registered record
    Registry ID
    NCT00068770
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    radiation therapy; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-10
    Completion
    2006-05
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventionradiation therapy; Celecoxib
    PhasePhase 2
    Registry statusTerminated

  • Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

    NCT00233675 · start 2003-08

    Registered record
    Registry ID
    NCT00233675
    Conditions
    General Anxiety Disorder
    Interventions
    GABITRIL (tiagabine hydrochloride; CEP-6671)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-08
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneral Anxiety Disorder
    InterventionGABITRIL (tiagabine hydrochloride; CEP-6671)
    PhasePhase 3
    Registry statusCompleted

  • Tiagabine for the Treatment of Cocaine Dependence - 1

    NCT00086255 · start 2002-10

    Registered record
    Registry ID
    NCT00086255
    Conditions
    Cocaine-Related Disorders
    Interventions
    Tiagabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-10
    Completion
    2004-06
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders
    InterventionTiagabine
    PhasePhase 2
    Registry statusCompleted

  • Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder

    NCT00208741 · start 2002-06

    Registered record
    Registry ID
    NCT00208741
    Conditions
    Social Anxiety Disorder
    Interventions
    Gabitril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-06
    Completion
    2003-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSocial Anxiety Disorder
    InterventionGabitril
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine

    NCT00218166 · start 2001-08

    Registered record
    Registry ID
    NCT00218166
    Conditions
    Cocaine-Related Disorders
    Interventions
    GABA Agonists
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-08
    Completion
    2005-05
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders
    InterventionGABA Agonists
    PhasePhase 2
    Registry statusCompleted

  • Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9

    NCT00015132 · start 1999-03

    Registered record
    Registry ID
    NCT00015132
    Conditions
    Cocaine-Related Disorders
    Interventions
    Sertraline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-03
    Completion
    2000-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders
    InterventionSertraline
    PhasePhase 2
    Registry statusCompleted